This study is testing a medication called Lumateperone (ITI-007) to see if it can help reduce stuttering symptoms in adults. You might be able to join if you are between 18 and 65 years old, have stuttering that started before age 8, and your stuttering is considered moderate to severe. Researchers will compare Lumateperone to a placebo (a pill with no active medicine) to see how well it works and if it's well-tolerated. Success will be measured by changes in your self-rated stuttering severity and how much your overall condition has improved. The study is currently unclear on its recruitment status and plans to enroll about 24 participants.

Study design

This is a double-blind, placebo-controlled study, meaning neither you nor your doctor will know if you are receiving Lumateperone or the placebo. It aims to enroll 24 adult participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your stuttering will be measured during the last seven days of the study, and your overall condition will be assessed based on symptoms over the past 7 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.